1. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses 
C. Hoffmann, M. Ernst, P. Meyer, E. Wolf, T. Rosenkranz, A. Plettenberg, A. Stoehr, H.-A. Horst, K. Marienfeld, C. Lange 
Clinical Microbiology and Infection 
Volume 13, Issue 5, Pages (May 2007)
DOI: /j x
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
Cumulative overall survival of patients diagnosed with toxoplasmic encephalitis at different time periods.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
ELISPOT results, either unstimulated (unst.), stimulated with soluble Toxoplasma gondii antigens alone, or co-stimulated with interleukin (IL)-12 or IL-15, respectively, for group A (left, five patients with an acute toxoplasmic encephalitis (TE) episode) and for group B (right, seven patients who did not develop a TE relapse within 12 months of discontinuation of maintenance therapy). PBMCs, peripheral blood mononuclear cells.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions